Nickan Research Institute Journal of Parathyroid Disease 2345-6558 4 1 2016 01 01 Correlation of fibroblast growth factor 23 in chronic kidney disease patients with biochemical parameters and outcomes 7 10 EN Anand Yuvaraj Georgi Abraham Madhusudan Vijayan Jayaraju Jayapal Saranya Kulanthaipandian Sanjeev Nair Journal Article Introduction: Fibroblast growth factor 23 (FGF23) is a phosphatonin that increases the rate of urinary excretion of phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, hence helping to mitigate hyperphosphatemia in patients with chronic kidney disease (CKD). Objectives: As there is a paucity of data in Indian CKD patients about the relevance of FGF23 levels, this study was undertaken at a tertiary care centre to correlate with various biochemical parameters and clinical outcome including mortality. Patients and Methods: A cross-sectional study was done in 76 CKD patients, with 58 males, 18 females, mean age 58.21 ± 14.08 years, ranging from 25 to 91 years, in 36 chronic renal disease on dialysis (CKD-stage 5 dialysis; CKD-5D) and 40 non-dialysis chronic kidney disease (ND-CKD) patients. Results: Intact FGF23 levels were higher in vegetarians than non-vegetarians, with mean FGF23 in vegetarians 378.72 ± 76.6 pg/ml, whereas in non-vegetarians 100.41 ± 41.3 pg/ml (P = 0.007). Higher values of intact FGF23 were associated with low EF (P = 0.008), high left ventricular (LV) mass index (g/m2) (P = 0.037) and high interventricular septal (IVS) thickness (mm) (P = 0.033). Conclusion: Patients with low ejection fraction, higher interventricular septal thickness and higher LV mass index on 2-dimensional echocardiogram (2D-Echo) had a higher